Atnaujinkite slapukų nuostatas

El. knyga: Lanzkowsky's Manual of Pediatric Hematology and Oncology

Edited by (Assistant Professor of Pediatrics, Hofstra Northwell School of Medicine, Hempstead, NY, USA), Edited by (North Shore-Long Island J), Edited by (Professor of Pediatrics and Molecular Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA)
  • Formatas: EPUB+DRM
  • Išleidimo metai: 30-Nov-2021
  • Leidėjas: Academic Press Inc
  • Kalba: eng
  • ISBN-13: 9780323853613
Kitos knygos pagal šią temą:
  • Formatas: EPUB+DRM
  • Išleidimo metai: 30-Nov-2021
  • Leidėjas: Academic Press Inc
  • Kalba: eng
  • ISBN-13: 9780323853613
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

Lanzkowsky’s Manual of Pediatric Hematology and Oncology, Seventh Edition remains the go-to clinical manual for the treatment and management of childhood cancers and blood disorders. It is a comprehensive book on patient management, replete with algorithms and flow diagrams, and includes a new section on vascular anomalies. Reflecting the considerable advances in the treatment and management of hematologic and oncologic diseases in children, the seventh edition of this successful clinical manual is entirely updated to incorporate all current treatment protocols, new drugs, and management approaches. Its concise and easy-to-read format, again, enables readers to make accurate diagnoses and treatment decisions without having to reference larger medical textbooks.

  • Designed to be easily readable and highly practical with over 400 illustrative tables, along with color diagrams and figures
  • New chapter on Pediatric Vascular Anomalies
  • New content on ‘blood avoidance’ programs to honor religious preferences
  • Discussions of new drugs and immunological therapies for cancers, along with discussions of increasing use of cytokine stimulants for hematologic disorders
  • Includes practical genetic evaluations providing a deeper understanding and advances in management of bone marrow failure diseases

Recenzijos

Praise for the 7th Edition: "Even in this digital age, Lanzkowskys Manual of Pediatric Hematology and Oncology remains the essential manual for pediatric hematology/oncology trainees, junior faculty and even senior investigators. The manual serves as a concise yet comprehensive guide that can steer physicians at any stage of their careers to best practices in areas both common and rare. The Manual is an authoritative and well-illustrated compendium that should be on the must have list of every pediatric hematologist and oncologist." --John M. Maris, MD, D'Angio Professor of Pediatrics, Children's Hospital of Philadelphia, Philadephia, Pennsylvania, USA

"Lanzkowskys Manual of Pediatric Hematology and Oncology, now in its 7th edition, has long had a fundamental place in the training of paediatric haematologists and oncologists, and provided subsequent support during their career due to its authoritative, concise and clear presentation of the speciality. It now constitutes a canonical work in haematology and as such acts as a reference tool to support the work of paediatric haematology departments and the personal development of senior clinicians and scientists. I very much welcome this new edition." --Professor Josu de la Fuente PhD FRCP FRCPI FRCPCH FRCPath, Consultant Haematologist and Director Paediatric Blood and Marrow Transplant Programme, St Marys Hospital and Imperial College London, London, UK

"I have been using Lanzkowskys Manual of Pediatric Hematology Oncology since it was first published in 1980. The Manual is a very valuable ready reference, written in a didactic way, filled with excellent algorithms and up-to-date treatment regimens, which are extremely useful to the clinician. I highly recommend it to all students and practitioners of pediatric hematology and oncology as an essential reference book." --Cyril Karabus MB, ChB, MMed Paed (UCT), DCH, FRCP (London), FRCP (Edin), Emeritus Associate Professor of Pediatrics, University of Cape Town, Cape Town, South Africa

"Lanzkowskys Manual of Pediatric Hematology and Oncology was the first book I bought when I started my fellowship at the NIH in 1993 and I am thrilled to see the seventh edition. I recently read the sixth edition, cover to cover, in preparation for becoming the Director of a large Pediatric Hematology Oncology Division. Amazingly, Dr. Lanzkowsky and his colleagues managed to incorporate in a reasonable-sized book, both the practical recipes for diagnosis and management of common as well as serious and rare oncologic and hematologic disorders. The new scientific revolution has been translated into precision medicine and brings us closer to curing every child with cancer and to the precise diagnosis and management of patients with serious hematologic disorders. These new advances and therapies are covered in the new edition in a clear and authoritative way. I recommend this book without hesitation to students, residents, fellows, attending physicians, nurses, diagnostic hematological laboratories, and yes, to Directors of Hematology Oncology services like myself." --Shai Izraeli, Prof of Hematological Malignancies at Tel Aviv University, Head of the Rina Zaizov Division of Pediatric Hematology Oncology at Schneider Childrens Medical Center of Israel, Treasurer and Head of Research the European Hematology Association.

List of contributors
xiii
About the editors xvii
Preface to the seventh edition xxi
Preface to the sixth edition xxiii
Preface to the fifth edition xxv
Preface to the fourth edition xxvii
Preface to the third edition xxix
Preface to the second edition xxxi
Preface to the first edition xxxiii
Introduction: Historic perspective (1955--2015) xxxv
1 Molecular and genomic methodologies for clinicians
1(6)
Jordan A. Shavit
Rajen J. Mody
Clinical molecular and genomic methodologies: goals
1(1)
Methods of genetic analysis
1(3)
Interpretation of genetic variants obtained from next-generation sequencing
4(1)
Applications of next-generation sequencing to oncology
4(2)
Interpreting and evaluating the results from clinical genetic testing
6(1)
Further reading and references
6(1)
2 Hematologic manifestations of systemic illness
7(30)
Brian M. Dulmovits
Lawrence C. Wolfe
Alterations to red blood cells related to organ-specific pathologies
7(5)
Alterations to white blood cells related to organ-specific pathologies
12(1)
Alterations to platelets and coagulation related to organ-specific pathologies
13(2)
General considerations for the hematologic sequelae of infection
15(1)
Viral and bacterial illnesses associated with marked hematologic sequelae
15(6)
Parasitic illnesses associated with marked hematologic sequelae
21(1)
Hemolytic uremic syndrome
22(1)
Autoimmune disease
23(2)
Anemia of inflammation
25(2)
Nutritional deficiencies and environmental exposures
27(1)
Marrow infiltrative disorders
28(6)
Further reading and references
34(3)
3 Classification and diagnosis of anemia in children and neonates
37(24)
Omar Niss
Charles T. Quinn
Classification and diagnosis
37(3)
Neonatal anemia
40(19)
Further reading and references
59(2)
4 Nutritional anemias
61(20)
Jacquelyn M. Powers
Overview
61(1)
Iron-deficiency anemia
61(10)
Megaloblastic anemia
71(9)
Further reading and references
80(1)
5 Lymphadenopathy and diseases of the spleen
81(10)
Philip Lanzkowsky
Lymphadenopathy
81(5)
Diseases of the spleen
86(3)
Further reading and references
89(2)
6 Bone marrow failure
91(34)
Adrianna Vlachos
Michelle Nash
Jeffrey M. Lipton
Aplastic anemia
91(11)
Inherited bone marrow failure syndromes
102(20)
Further reading and references
122(3)
7 General considerations of hemolytic diseases, red cell membrane, and enzyme defects
125(26)
Lionel Blanc
Lawrence C. Wolfe
Clinical features of hemolytic disease
125(1)
Laboratory findings
126(2)
Membrane defects
128(10)
Paroxysmal nocturnal hemoglobinuria
138(4)
Enzyme defects
142(6)
Further reading and references
148(3)
8 Extracorpuscular hemolytic anemia
151(10)
Anshulvagrecha
Lawrence C. Wolfe
Immune hemolytic anemia
151(7)
Nonimmune hemolytic anemia
158(1)
Further reading and references
159(2)
9 Hemoglobinopathies
161(32)
Eugene Khandros
Janet L. Kwiatkowski
Sickle cell disease
161(18)
Sickle cell trait (heterozygous form, AS)
179(1)
Hemoglobin C
179(1)
Hemoglobin E
180(1)
Unstable hemoglobins
180(1)
Thalassemias
180(11)
Further reading and references
191(2)
10 Primary and secondary erythrocytosis
193(14)
Tsewang Tashi
Josef T. Prchal
Erythrocytosis or polycythemia
193(2)
Primary erythrocytosis
195(2)
Secondary erythrocytosis
197(6)
Diagnostic approach to erythrocytosis
203(1)
Further reading and references
204(3)
11 Disorders of white blood cells
207(30)
Kelly Walkovich
James A. Connelly
Leukocytosis
207(1)
Leukopenia
208(1)
Neutrophil disorders
208(9)
Monocytes disorders
217(3)
Eosinophil disorders
220(6)
Basophil disorders
226(2)
Lymphocyte disorders
228(7)
Dedication
235(1)
Further reading and references
235(2)
12 Disorders of platelets
237(50)
Catherine Mcguinn
James B. Bussel
Thrombocytopenia in the newborn
237(11)
Inherited thrombocytopenias
248(9)
Immune thrombocytopenic purpura
257(8)
Other causes of thrombocytopenia
265(5)
Thrombocytosis
270(2)
Qualitative platelet disorders
272(8)
Inherited vascular and connective tissue disorders
280(1)
Nonthrombocytopenic purpura
281(1)
Laboratory evaluation of platelets and platelet function
282(2)
Further reading and references
284(3)
13 Disorders of coagulation
287(54)
Susmita N. Sarangi
Suchitra S. Acharya
Hemostatic disorders
287(10)
Acquired coagulation factor disorders
297(2)
Inherited coagulation factor disorders
299(16)
Thrombotic disorders
315(17)
Antithrombotic therapy
332(7)
Further reading and references
339(2)
14 Vascular anomalies
341(16)
Rachel Kessel
Francine Blei
Ionela Iacobas
Introduction
341(1)
Vascular tumors
341(2)
Simple vascular malformations
343(1)
Diagnostic work-up for vascular lesions
344(3)
Management
347(1)
Evaluation and monitoring of a vascular hepatic tumor
348(2)
Vascular anomaly syndromes
350(6)
Further reading and references
356(1)
15 Histiocytic disorders
357(20)
Olive S. Eckstein
Carl E. Allen
Introduction
357(1)
Langerhans cell histiocytosis
357(12)
Other histiocytic disorders
369(2)
Hemophagocytic lymphohistiocytosis (hemophagocytic syndromes)
371(3)
Further reading and references
374(3)
16 Lymphoproliferative disorders
377(14)
David T. Teachey
Angioimmunoblastic lymphadenopathy with dysproteinemia
377(1)
Small lymphocytic infiltrates of the orbit and conjunctiva (ocular adnexal lymphoid proliferation, pseudolymphoma, benign lymphoma, atypical lymphocytic infiltrates)
378(1)
Angiocentric immunolymphoproliferative disorders
378(1)
Castleman disease (angiofollicular lymph node hyperplasia, benign giant lymph node hyperplasia, angiomatous lymphoid hamartoma)
379(1)
Epstein---Barr virus-associated Lymphoproliferative disorders in immunocompromised individuals
380(5)
X-linked lymphoproliferative syndrome
385(1)
Autoimmune lymphoproliferative syndrome
386(3)
Lymphomatoid papulosis in children
389(1)
Further reading and references
390(1)
17 Myelodysplastic syndromes and myeloproliferative disorders
391(22)
Inga Hofmann
Nobuko Hijiya
Mohamed Tarek Elghetany
Myelodysplastic syndromes
391(7)
Myeloid proliferations in children with Down syndrome (DS)
398(1)
Juvenile myelomonocytic leukemia
398(5)
Myeloproliferative neoplasms
403(6)
Further reading and references
409(4)
18 Acute lymphoblastic leukemia
413(26)
Pallavi M. Pillai
William L. Carroll
Incidence of ALL
413(1)
Etiology
413(1)
Clinical features of ALL
414(2)
Diagnosis
416(1)
Classification
417(3)
Cytogenetics and molecular genetics of ALL
420(1)
Prognostic factors
421(1)
Treatment
422(7)
Infant leukemia
429(1)
Philadelphia-positive ALL
430(1)
Ph-like ALL
431(1)
Down syndrome and ALL
431(1)
Relapse in children with ALL
431(2)
Immunotherapy for ALL
433(1)
Central nervous system relapse
434(2)
Long-term effects of ALL therapy
436(1)
Future drugs in ALL therapy
436(1)
Further reading and references
437(2)
19 Acute myeloid leukemia
439(20)
Arlene Redner
Rachel Kessel
Incidence and epidemiology
439(1)
Etiology and predisposing conditions
439(1)
Clinical features
440(1)
Diagnostic and monitoring studies
441(1)
Classification of AML
442(5)
Supportive care
447(1)
The treatment of newly diagnosed AML
448(2)
Prognosis of newly diagnosed AML
450(1)
Relapsed and refractory AML
450(1)
Novel therapeutic approaches
451(3)
Acute promyelocytic leukemia
454(2)
AML special subgroups
456(1)
Further reading and references
457(2)
20 Hodgkin lymphoma
459(14)
Christine M. Smith
Debra L. Friedman
Etiology and epidemiology
459(1)
Risk factors
459(1)
Biology
460(1)
Pathology
460(1)
Clinical presentation
461(3)
Diagnostic evaluation and staging
464(1)
Prognostic factors
465(1)
Treatment
466(5)
Follow-up evaluations
471(1)
Further reading and references
471(1)
Web resources
472(1)
21 Non-Hodgkin lymphoma
473(12)
Mary S. Huang
Howard J. Weinstein
Introduction
473(1)
Incidence and epidemiology
473(1)
Pathologic classification
474(1)
Clinical features
475(1)
Diagnosis
475(1)
Staging
476(1)
Prognosis
476(1)
Management
477(2)
Non-Hodgkin Lymphoma Subtypes
479(3)
Further reading and references
482(3)
22 Central nervous system tumors
485(22)
Derek Hanson
Mark P. Atlas
Pathology
485(1)
Clinical manifestations
486(2)
Diagnostic evaluation
488(2)
Treatment
490(2)
Specific CNS tumors
492(11)
Genetic syndromes related to brain tumors
503(1)
Further reading and references
504(3)
23 Neuroblastoma
507(18)
Julie Krystal
Elizabeth Sokol
Rochelle Bagatell
Epidemiology
507(1)
Predisposition
507(1)
Pathology and biology
507(1)
Clinical features
508(2)
Diagnosis and staging
510(1)
Treatment modalities
511(2)
Prognosis, risk stratification, and therapy
513(9)
Neuroblastoma in the adolescent and young adult
522(1)
Further reading and references
522(3)
24 Renal tumors
525(16)
Anne B. Warwick
Jeffrey S. Dome
Wilms tumor
525(13)
Nephroblastomatosis
538(1)
Congenital mesoblastic nephroma
538(1)
Clear cell sarcoma of the kidney
539(1)
Rhabdoid tumor of the kidney
539(1)
Renal cell carcinoma
539(1)
Further reading and references
540(1)
25 Rhabdomyosarcoma and other soft-tissue sarcomas
541(22)
Seema Amin
Carolyn Fein Levy
Incidence and epidemiology
541(1)
Pathologic and genetic classification
542(3)
Clinical features
545(2)
Diagnostic evaluation
547(2)
Staging
549(2)
Prognosis
551(1)
Treatment
552(6)
Follow-up after completion of therapy
558(1)
Recurrent disease
559(1)
Future perspectives
560(1)
Further reading and references
561(2)
26 Malignant bone tumors
563(20)
Katrina Winsnes
Noah Federman
Osteosarcoma
563(9)
Ewing sarcoma family of tumors
572(6)
Other bone tumors
578(3)
Further reading and references
581(2)
27 Retinoblastoma
583(14)
Amish Shah
Ann Leahey
Incidence
583(1)
Classification
583(2)
Risk for second malignant neoplasms
585(1)
Pathology
586(1)
Clinical features
586(1)
Differential diagnosis
587(1)
Patterns of spread
587(1)
Diagnostic procedures
588(1)
Classification
588(1)
Treatment
589(1)
Treatment of intraocular RB
590(4)
Treatment of recurrent RB
594(1)
Treatment of extraocular RB
594(1)
Posttreatment management
594(1)
Further reading and references
595(2)
28 Extracranial germ cell tumors
597(16)
Adriana Fonseca
Thomas A. Olson
Epidemiology
597(1)
Biology
597(1)
Histology
597(1)
Molecular characteristics
598(1)
Clinical features
599(1)
Diagnostic evaluation
600(1)
Staging and risk stratification
601(1)
Treatment
601(6)
Risk-stratified therapeutic approaches
607(3)
Relapsed and resistant germ cell tumors
610(1)
Further reading and references
610(3)
29 Hepatic tumors
613(10)
Kathryn S. Sutton
Thomas A. Olson
Incidence
613(1)
Epidemiology
613(2)
Pathology
615(1)
Clinical features
615(1)
Diagnostic evaluation
615(2)
Staging and risk stratification
617(1)
Treatment
618(2)
Further reading and references
620(3)
30 Hematopoietic stem cell transplantation and cellular therapy
623(36)
Hisham Abdel-Azim
Michael A. Pulsipher
Allogeneic stem cell transplantation
623(5)
HSC sources, collection, and manipulation
628(2)
Graft manipulation postcollection
630(1)
Medical evaluation of HSC donors
630(1)
Pretransplantation preparative regimens (conditioning)
631(4)
Engraftment
635(1)
Complications of HSCT
636(16)
Recent advances in HSCT
652(3)
Outcomes
655(2)
Further reading and references
657(2)
31 Management of oncologic emergencies
659(16)
Jason L. Freedman
Caitlin W. Elgarten
Susan R. Rheingold
Metabolic emergencies
659(4)
Cardiothoracic emergencies
663(1)
Abdominal emergencies
664(2)
Renal emergencies
666(2)
Neurologic emergencies
668(1)
Endocrine emergencies
669(2)
Treatment-associated emergencies
671(2)
Further reading and references
673(2)
32 Supportive care of patients with cancer
675(38)
Anurag K. Agrawal
James Feusner
Management of infectious complications
675(11)
Recognition and management of nausea and vomiting
686(2)
Mucositis
688(2)
Pain management
690(6)
Nutritional status of the oncology patient
696(2)
Utilization of hematopoietic growth factors
698(2)
Management of acute radiation side effects
700(3)
Management of CVCs
703(5)
Posttreatment immunizations
708(1)
Palliative care
709(1)
Further reading and references
710(3)
33 Evaluation, investigations, and management of late effects of childhood cancer
713(22)
Miriam Radinsky
Jonathan D. Fish
Models of survivorship care
713(1)
Interventions and screening guidelines
714(2)
Organ system---specific late effects
716(17)
Future considerations
733(1)
Further reading and references
733(2)
34 Psychosocial factors impacting children with cancer and their families
735(14)
Amy Nadel
Time of diagnosis
735(5)
Treatment initiation
740(2)
Illness stabilization
742(1)
During relapses and recurrences
743(1)
Treatment outcomes: the unsuccessful course
744(2)
Treatment outcomes: the successful course
746(1)
Conclusion
747(1)
Further reading and references
748(1)
35 Pediatric blood banking principles and transfusion medicine practices
749(18)
Maha Al-Ghafry
Cassandra D. Josephson
Introduction
749(1)
Immunohematology
749(1)
Donor recruitment and testing
750(1)
Blood collection and processing
751(2)
Blood products
753(3)
Blood component modification and administration
756(2)
Transfusion reactions
758(3)
Special populations
761(2)
Therapeutic apheresis
763(1)
Patient blood management
764(1)
Further reading and references
765(2)
Appendix 1 Hematological reference values 767(14)
Index 781
Jonathan D. Fish, MD is Assistant Professor of Pediatrics at the Hofstra Northwell School of Medicine. He is Director of the Survivors Facing Forward Program, a long-term follow-up program for survivors of childhood cancer, in the division of Pediatric Hematology/Oncology and Stem Cell Transplantation at the Steven and Alexandra Cohen Childrens Medical Center of New York. He holds a B.A., with distinction, from the University of Western Ontario and received his M.D. degree, magna cum laude, from the Upstate Medical Center of the State University of New York. He did his Pediatric training at the the Schneider Childrens Hospital, New Hyde Park, NY ( Presently known as the Steven and Alexandra Childrens Medical Center of New York) and completed his Pediatric Hematology-Oncology fellowship training at the Childrens Hospital of Philadelphia. Dr. Fish received the American Society of Pediatric Hematology-Oncology Young Investigator Award in 2008. His clinical and research interest is on the late effects of childhood cancer treatment and survivorship care. Jeffrey M. Lipton, MD, PhD is the Chief of Hematology/Oncology and Stem Cell Transplantation at the Steven and Alexandra Cohen Childrens Medical Center of New York and Center Head, Patient Oriented Research, The Feinstein Institute for Medical Research. He is Professor, Elmezzi Graduate School of Molecular Medicine, The Feinstein Institute for Medical Research and Professor of Pediatrics and Molecular Medicine at the Hofstra North Shore LIJ School of Medicine. He holds a B.A. from Queens College, City University of New York, a Ph.D in Chemistry from Syracuse University and an M.D. degree, magna cum laude, from Saint Louis University Medical School. He did his Pediatric residency training at the Childrens Hospital, Boston, MA and his Pediatric Hematology/Oncology fellowship training at the Childrens Hospital and the Sidney Farber Cancer Institute (now DFCI) in Boston. Dr. Lipton is a Past-President of the American Society of Pediatric Hematology/Oncology (ASPHO). His main interest is bone marrow failure. Dr. Philip Lanzkowsky was born in Cape Town on March 17, 1932 and graduated high school from the South African College and obtained his MB ChB degree from the University of Cape Town School of Medicine in 1954 and his Doctorate degree in 1959 for his thesis on Iron Deficiency Anemia In Children. He completed a pediatric residency at the Red Cross War Memorial Childrens Hospital in Cape Town in 1960. After working in Pediatrics at the University of Edinburgh and at St Marys Hospital of the University of London, Dr. Lanzkowsky did a pediatric Hematology-Oncology fellowship at Duke University School of Medicine and at the University of Utah.

In 1963 he was appointed Consultant Pediatrician and Pediatric Hematologist to the Red Cross War Memorial Childrens Hospital at the University of Cape Town and introduced Pediatric Hematology and Oncology as a distinct discipline. In 1965 he was appointed Director of Pediatric Hematology and Associate Professor of Pediatrics at the New York Hospital-Cornell University School of Medicine.

In 1970 he was appointed Professor of Pediatrics and Chairman of Pediatrics at Long Island Jewish Medical Center and established a division of Pediatric Hematology-Oncology which he directed until 2000. He was the founder of the Schneider Childrens Hospital, which he developed, planned, and was the hospitals Executive Director and Chief of Staff from its inception in 1983 until 2010.

Dr. Lanzkowsky has received numerous honors and awards and has lectured extensively at various institutions and medical schools in the United States and around the world. In addition to having been the author of five editions of the Manual of Pediatric Hematology and Oncology used by clinicians worldwide, he is the author of How It All Began: The History of a Childrens Hospital and over 280 scientific papers, abstracts, monographs, and book chapters.

Dr. Lanzkowskys medical writings have been prodigious. His seminal contributions to the medical literature have included the first description of the relationship of pica to iron-deficiency anemia (Arch. Dis Child., 1959), Effects of timing of clamping of umbilical cord on infants hemoglobin level (Br. Med. J., 1960), Normal oral D-xylose test values in children (New Engl. J. Med., 1963), Normal coagulation factors in women in labor and in the newborn (Thromboses at Diath. Hemorr., 1966), Erythrocyte abnormalities induced by malnutrition (Br. J. Haemat., 1967), Radiologic features in iron deficiency anemia (Am. J. Dis. Child., 1968), Isolated defect of folic acid absorption associated with mental retardation (Blood, 1969; Am. J. Med, 1970), Disaccharidase levels in iron deficiency (J. Pediat., 1981) and Hexokinase New Hyde Park” in a Chinese kindred (Am. J. Hematol., 1981).